July 21, 2021
Myovant Sciences, a subsidiary of Sumitomo Dainippon Pharma, said on July 20 that the European Commission has approved its relugolix combination drug (relugolix + estradiol + norethindrone) for the treatment of women with uterine fibroids. The drug now called Ryeqo...read more